Jasper Therapeutics appoints new members to board of directors

Klein joins from CRISPR Therapeutics.

MM+M Staff

September 29, 2021

3:00 pm

Jasper Therapeutics announced it has appointed Lawrence Klein and Chris Nolet to its board of directors, where they’ll help guide the development of the company’s anti-CD117 monoclonal antibody and stem cell platform. Klein serves as COO at CRISPR Therapeutics, and Nolet brings experience as an audit partner and business advisor in life sciences.

“We are pleased to appoint Lawrence and Chris to the Jasper board of directors to add additional expertise to the team in cellular and gene therapy development and to build a leading public biotechnology company,” Bill Lis, executive chairman and CEO at Jasper, said in a statement.

From Our Partners

Living brands: How to build brands in the age of omnichannel

Partner Content

Living brands: How to build brands in the age of omnichannel

This podcast looks at how to leverage advancements in data, technology, AI and content development in order to become a Living Brand.

Partner Content

The new brand.com experience

How healthcare manufacturers can improve customer engagement, drive high-value activity and inform future strategy with conversational AI.

Shifting market trends are transforming how pharma marketers find, target and engage with patients and providers

Partner Content

Shifting market trends are transforming how pharma marketers find, target and engage with patients and providers

The Healthcare Marketers Trend Survey shows that, as far as channel usage goes, more growth occurred in newer tactics like non-linear video and streaming audio than in some of the more traditional ones.

A Big C Shift: Rebranding cancer to reflect advances in oncology

Partner Content

A Big C Shift: Rebranding cancer to reflect advances in oncology

Pivoting people’s perception of the disease to match the realities of treatment.